Beta amyloid-targeted therapeutic antibody

Home » Beta amyloid-targeted therapeutic antibody

Beta amyloid-targeted therapeutic antibody

Early Discovery

Lead Generation

Lead Optimisation

Preclinical Development

Modality

Biotherapeutics

Therapeutic area

Neuroscience

Advantages

A novel approach to specifically target Aβ N-terminal oligomers

Background info

TAPAS specifically recognises the truncated toxic forms pyroglutamate (AβpE3) and Aβ4-42, but not Aβ1-42 showed efficacy in vivo in different models of Alzheimer’s disease.

Indication

Alzheimer’s Disease

Intellectual property

Pending patent applications: WO20070225; Granted patents: EP2847217 B1; EP3269736 B1; US9617332 BB; HK11207869 B

Contact us

Name(Required)

First Last

Organisation

Role

Email(Required)

Enter Email Confirm Email

Phone number

Comments(Required)

Please let us know what's on your mind. Have a question for us? Ask away.

In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email info@lifearc.org.

Please see our Privacy Policy in relation to the personal data you submit to us through this page.